AnaptysBio, Inc. is a biotechnology company. It involved in the discovery and development of therapeutic antibodies for inflammation and immuno-oncology primarily in the Unites states. AnaptysBio, Inc. is based in San Diego, California.
| Revenue (Most Recent Fiscal Year) | $91.28M |
| Net Income (Most Recent Fiscal Year) | $-145.23M |
| PE Ratio (Current Year Earnings Estimate) | -- |
| PE Ratio (Trailing 12 Months) | -- |
| PEG Ratio (Long Term Growth Estimate) | -- |
| Price to Sales Ratio (Trailing 12 Months) | 5.92 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 19.61 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | -- |
| Pre-Tax Margin (Trailing 12 Months) | -125.66% |
| Net Margin (Trailing 12 Months) | -125.70% |
| Return on Equity (Trailing 12 Months) | -282.47% |
| Return on Assets (Trailing 12 Months) | -30.79% |
| Current Ratio (Most Recent Fiscal Quarter) | 8.25 |
| Quick Ratio (Most Recent Fiscal Quarter) | 8.25 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.00 |
| Inventory Turnover (Trailing 12 Months) | -- |
| Book Value per Share (Most Recent Fiscal Quarter) | $1.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $-1.28 |
| Earnings per Share (Most Recent Fiscal Year) | $-5.12 |
| Diluted Earnings per Share (Trailing 12 Months) | $-4.85 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 29.38M |
| Free Float | 19.54M |
| Market Capitalization | $662.82M |
| Average Volume (Last 20 Days) | 0.53M |
| Beta (Past 60 Months) | -0.20 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 33.50% |
| Percentage Held By Institutions (Latest 13F Reports) | -- |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |